Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 2, 2019

View Archived Issues

APPBP2 as a novel therapeutic target in NSCLC

Selective targeting of PARP-2 inhibits AR-positive prostate cancer growth

Myocardial ischemia/reperfusion injury is reduced by prostacyclin analogue-loaded nanoparticles

AAV-eCD4-Ig protects rhesus macaques from SIVmac239 challenges

Commensal Neisseria fight pathogenic relatives in "tribal warfare"

Positive interim data presented for AAV gene therapy in children with CLN6 Batten disease

AZD-0530 shows no statistically significant effect on cerebral metabolic decline in AD

First-in-human data presented for the zwitterionic near-infrared fluorophore ZW800-1

JMJD6 as a novel therapeutic target in neuroblastoma

Rewind Therapeutics to discover drugs for myelin-related neurological diseases

Phase I study of PN-943 demonstrates sustained dose-related target engagement activity

Promedior presents phase II data on PRM-151 in patients with IPF

Zeno Royalties & Milestones patents Bcl-2 inhibitors

Lifesci Pharmaceuticals divulges KLKB1 inhibitors

Momenta Pharmaceuticals launches phase II/III study of nipocalimab in wAIHA

Integral BioSciences discloses new TGFR-1 and MAPK14 inhibitors

Aurigene Discovery Technologies describes new anticancer agents

New glucose-lowering compounds presented by Daiichi Sankyo

First patient dosed in phase IIa study of ABX-464 for the treatment of RA

Prokaryotics receives support for its immune potentiation program

Novartis initiates first-in-human trial of CD19-specific CAR-T cells

Recruitment ongoing in phase I study of BI-754132

T20K demonstrates favorable safety and tolerability in first-in-human study

IDMC recommends stopping PHOCUS study of Pexa-Vec

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...